News & Updates

Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.

Using low-dose aspirin appears to reduce the risk of colorectal cancer (CRC) in adults, suggests a study.

Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.

Use of aspirin, although safe, does not appear to provide any meaningful beneficial effects for diabetic retinopathy (DR), a study has shown.

Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.

The human monoclonal antibody pamrevlumab fails to deliver benefit for patients with idiopathic pulmonary fibrosis (IPF) in the phase III ZEPHYRUS-1 trial.